[go: up one dir, main page]

NO20064418L - Nye amido-substituerte hydroksy-6-fenylfenantridiner - Google Patents

Nye amido-substituerte hydroksy-6-fenylfenantridiner

Info

Publication number
NO20064418L
NO20064418L NO20064418A NO20064418A NO20064418L NO 20064418 L NO20064418 L NO 20064418L NO 20064418 A NO20064418 A NO 20064418A NO 20064418 A NO20064418 A NO 20064418A NO 20064418 L NO20064418 L NO 20064418L
Authority
NO
Norway
Prior art keywords
phenylphenanthridines
substituted hydroxy
novel amido
novel
amido
Prior art date
Application number
NO20064418A
Other languages
English (en)
Other versions
NO337457B1 (no
Inventor
Thomas Beckers
Thomas Maier
Petra Gimmnich
Matthias Vennemann
Thomas Bar
Frank Dullweber
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of NO20064418L publication Critical patent/NO20064418L/no
Publication of NO337457B1 publication Critical patent/NO337457B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)

Abstract

Forbindelser med en bestemt formel I, hvori R1, R2, R3, R4, R5, R6 og R7 har betydningene indikert i beskrivelsen, er nye effektive HDAC-inhibitorer.
NO20064418A 2004-03-11 2006-09-29 Nye amido-substituerte hydroksy-6-fenylfenantridiner NO337457B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101003 2004-03-11
PCT/EP2005/051086 WO2005087724A2 (en) 2004-03-11 2005-03-10 Sulphonylpyrroles as hdac inhibitors

Publications (2)

Publication Number Publication Date
NO20064418L true NO20064418L (no) 2006-12-08
NO337457B1 NO337457B1 (no) 2016-04-18

Family

ID=34928899

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064418A NO337457B1 (no) 2004-03-11 2006-09-29 Nye amido-substituerte hydroksy-6-fenylfenantridiner

Country Status (25)

Country Link
US (5) US7842820B2 (no)
EP (2) EP1725528B1 (no)
JP (1) JP4856623B2 (no)
KR (1) KR101130556B1 (no)
CN (1) CN1926103B (no)
AR (1) AR048427A1 (no)
AU (1) AU2005221834B2 (no)
BR (1) BRPI0508464B8 (no)
CA (1) CA2558552C (no)
CY (1) CY1114284T1 (no)
DK (1) DK1725528T3 (no)
EA (1) EA012451B1 (no)
ES (1) ES2430371T3 (no)
HR (1) HRP20130810T1 (no)
IL (1) IL177168A (no)
ME (1) ME02122B (no)
NO (1) NO337457B1 (no)
NZ (1) NZ549251A (no)
PL (1) PL1725528T3 (no)
PT (1) PT1725528E (no)
RS (1) RS52937B (no)
SI (1) SI1725528T1 (no)
TW (1) TWI353977B (no)
WO (1) WO2005087724A2 (no)
ZA (1) ZA200606315B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
EP1725528B1 (en) 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
ES2552338T3 (es) * 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
RS51151B (sr) * 2005-03-15 2010-10-31 4Sc Ag N-sulfonilpiroli i njihova upotreba kao inhibitora histon deacetilaze
US20090117074A1 (en) * 2005-04-07 2009-05-07 Nycomed Gmbh Sulfonylpyrroles as Histone Deacetylase Inhibitors
NZ541788A (en) * 2005-08-11 2007-12-21 Auckland Uniservices Ltd Conducting polymers and their use in oligonucleotide (ODN) probes
HRP20120399T1 (hr) * 2005-09-21 2012-06-30 4Sc Ag Novi sulfonilpiroli kao inhibitori hdac
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
PT1975158E (pt) * 2005-12-27 2011-09-23 Ct Nac Investigaciones Oncologicas Cnio Novos derivados de pirrole com actividade inibidora de histona desacetilase
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
EP2100878A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Novel method for the production of sulphonylpyrroles as HDAC inhibitors
ES2605815T3 (es) * 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
CN101941948A (zh) * 2009-07-10 2011-01-12 南开大学 点击化学合成具有分支结构的组蛋白去乙酰酶抑制剂
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
ES2680224T3 (es) 2013-03-15 2018-09-05 Biomarin Pharmaceutical Inc. Inhibidores de HDAC
WO2015058106A1 (en) 2013-10-18 2015-04-23 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
CN105801464B (zh) * 2014-12-29 2019-05-28 成都先导药物开发有限公司 吡咯酰胺类化合物及其制备方法与用途
KR20180130565A (ko) 2016-04-14 2018-12-07 4에스체 악티엔게젤샤프트 아시아 환자에서의 레스미노스타트의 의학적 적용
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療
WO2019200238A1 (en) 2018-04-14 2019-10-17 Dynavax Technologies Corporation Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
SG11202009667UA (en) 2018-04-17 2020-11-27 4Sc Ag Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment
TW202114659A (zh) 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
ES2107557T3 (es) 1991-12-10 1997-12-01 Shionogi & Co Derivado de acido hidroxamico a base de sulfonamida aromatica.
AU5886296A (en) 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
KR20070053362A (ko) * 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
AU2044401A (en) 1999-11-23 2001-06-04 Merck & Co., Inc. Pyrazinone thrombin inhibitors
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
KR20040022238A (ko) * 2001-08-09 2004-03-11 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
MXPA04007775A (es) * 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
AU2003298567B9 (en) 2002-08-29 2009-07-23 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
US20050197336A1 (en) 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
EP1725528B1 (en) * 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
GB2415703A (en) 2004-07-02 2006-01-04 Hewlett Packard Development Co Liquid crystal display device
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7432808B2 (en) 2004-12-15 2008-10-07 Intel Corporation Wireless module enabled component carrier for parts inventory and tracking
DE602005026169D1 (de) 2004-12-17 2011-03-10 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
RS51151B (sr) * 2005-03-15 2010-10-31 4Sc Ag N-sulfonilpiroli i njihova upotreba kao inhibitora histon deacetilaze
US20090117074A1 (en) * 2005-04-07 2009-05-07 Nycomed Gmbh Sulfonylpyrroles as Histone Deacetylase Inhibitors
HRP20120399T1 (hr) 2005-09-21 2012-06-30 4Sc Ag Novi sulfonilpiroli kao inhibitori hdac
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts

Also Published As

Publication number Publication date
US20110166140A1 (en) 2011-07-07
AU2005221834A1 (en) 2005-09-22
KR101130556B1 (ko) 2012-03-30
US8399505B2 (en) 2013-03-19
JP4856623B2 (ja) 2012-01-18
IL177168A (en) 2012-03-29
BRPI0508464A (pt) 2007-07-31
US20070184979A1 (en) 2007-08-09
RS52937B (sr) 2014-02-28
US20130079347A1 (en) 2013-03-28
SI1725528T1 (sl) 2013-11-29
US8067615B2 (en) 2011-11-29
HK1102583A1 (en) 2007-11-30
HRP20130810T1 (en) 2013-09-30
DK1725528T3 (da) 2013-09-02
AR048427A1 (es) 2006-04-26
US20100261721A1 (en) 2010-10-14
BRPI0508464B8 (pt) 2021-05-25
TWI353977B (en) 2011-12-11
WO2005087724A2 (en) 2005-09-22
EP1725528A2 (en) 2006-11-29
EA200601587A1 (ru) 2007-04-27
ES2430371T3 (es) 2013-11-20
KR20060131927A (ko) 2006-12-20
JP2007527902A (ja) 2007-10-04
CA2558552C (en) 2015-06-02
CN1926103B (zh) 2012-12-19
CN1926103A (zh) 2007-03-07
NZ549251A (en) 2010-05-28
CA2558552A1 (en) 2005-09-22
US20100261761A1 (en) 2010-10-14
EP1725528B1 (en) 2013-05-29
PL1725528T3 (pl) 2013-12-31
US7842820B2 (en) 2010-11-30
CY1114284T1 (el) 2016-08-31
IL177168A0 (en) 2006-12-10
NO337457B1 (no) 2016-04-18
BRPI0508464B1 (pt) 2020-02-11
ME02122B (me) 2014-02-28
EP2272827A1 (en) 2011-01-12
ZA200606315B (en) 2008-02-27
US8969401B2 (en) 2015-03-03
EA012451B1 (ru) 2009-10-30
WO2005087724A3 (en) 2005-12-08
TW200538432A (en) 2005-12-01
PT1725528E (pt) 2013-09-26
AU2005221834B2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
NO20064418L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner
NO20081797L (no) Nye solfonylpyrroler som inhibitorer av HDAC
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
NO20073921L (no) Triazoloftalaziner
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
NO20070606L (no) Inhibitorer av IAP
TW200745027A (en) Novel sulphonylpyrroles
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
HRP20050228A2 (en) Novel phenanthridines
NO20025811L (no) Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer
NO20064415L (no) Nye amido-substituerte hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20082118L (no) Heterocykliske CETP-inhibitorer
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
NO20064491L (no) Nye difluomtoksysubstituee hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon
NO20061789L (no) Aminopyridinderivater som induserbare NO-syntaseinhibitorer
NO20064417L (no) Nye isoamidosubstituertehydroksy-6-fenylfenantridiner
ATE517623T1 (de) Verwendung von methylphenidat-derivaten
NO20045123L (no) Nitroserte imidazopyridiner
ATE348803T1 (de) Tryptase-inhibitoren
ATE390419T1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-o - derivate als pde4-inhibitoren
NO20053562L (no) Nye aminobenzofenonforbindelser

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104